Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 52 entries
Sorted by: Best Match Show Resources per page
A comparison of cocaine vs lidocaine- oxymetazoline in nasal procedures.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India

Traver CP, Noorily AD, Sakai CS, Choradia V.
PMID: 23119265
Indian J Otolaryngol Head Neck Surg. 1997 Jan;49(1):85. doi: 10.1007/BF02991729.

No abstract available.

Cite
Traver CP, Noorily AD, Sakai CS, et al. A comparison of cocaine vs lidocaine- oxymetazoline in nasal procedures. Indian J Otolaryngol Head Neck Surg. 1997;49(1):85doi: 10.1007/BF02991729.
Traver, C. P., Noorily, A. D., Sakai, C. S., & Choradia, V. (1997). A comparison of cocaine vs lidocaine- oxymetazoline in nasal procedures. Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 49(1), 85. https://doi.org/10.1007/BF02991729
Traver, C P, et al. "A comparison of cocaine vs lidocaine- oxymetazoline in nasal procedures." Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India vol. 49,1 (1997): 85. doi: https://doi.org/10.1007/BF02991729
Traver CP, Noorily AD, Sakai CS, Choradia V. A comparison of cocaine vs lidocaine- oxymetazoline in nasal procedures. Indian J Otolaryngol Head Neck Surg. 1997 Jan;49(1):85. doi: 10.1007/BF02991729. PMID: 23119265; PMCID: PMC3450731.
Copy Download .nbib Format: NLM
WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials.

Journal of the American Academy of Dermatology

Stein-Gold L, Kircik LH, Draelos ZD, Werschler P, DuBois J, Lain E, Baumann L, Goldberg DJ, Kaufman J, Tanghetti EA, Alvandi N, Weng E, Berk DR, Ahluwalia G.
PMID: 29409915
J Am Acad Dermatol. 2018 Jan 31; doi: 10.1016/j.jaad.2018.01.028. Epub 2018 Jan 31.

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.

Cite
Stein-Gold L, Kircik LH, Draelos ZD, et al. WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials. J Am Acad Dermatol. 2018;doi: 10.1016/j.jaad.2018.01.028.
Stein-Gold, L., Kircik, L. H., Draelos, Z. D., Werschler, P., DuBois, J., Lain, E., Baumann, L., Goldberg, D. J., Kaufman, J., Tanghetti, E. A., Alvandi, N., Weng, E., Berk, D. R., & Ahluwalia, G. (2018). WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials. Journal of the American Academy of Dermatology, . https://doi.org/10.1016/j.jaad.2018.01.028
Stein-Gold, Linda, et al. "WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials." Journal of the American Academy of Dermatology vol. (2018). doi: https://doi.org/10.1016/j.jaad.2018.01.028
Stein-Gold L, Kircik LH, Draelos ZD, Werschler P, DuBois J, Lain E, Baumann L, Goldberg DJ, Kaufman J, Tanghetti EA, Alvandi N, Weng E, Berk DR, Ahluwalia G. WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trials. J Am Acad Dermatol. 2018 Jan 31; doi: 10.1016/j.jaad.2018.01.028. Epub 2018 Jan 31. PMID: 29409915.
Copy Download .nbib Format: NLM
Successful treatment of knee erythromelalgia with topical oxymetazoline.

Clinical and experimental dermatology

Altemir A, Iglesias-Sancho M, Barrabés-Torrella C, Sanchez-Regaña M, Salleras-Redonnet M.
PMID: 34905256
Clin Exp Dermatol. 2021 Dec 14; doi: 10.1111/ced.15060. Epub 2021 Dec 14.

Erythromelalgia is an infrequent syndrome with a profound impact on quality of life. Its management is usually challenging and multiple treatments have been reported with variable response rates. To the best of our knowledge, we present the first case...

Cite
Altemir A, Iglesias-Sancho M, Barrabés-Torrella C, et al. Successful treatment of knee erythromelalgia with topical oxymetazoline. Clin Exp Dermatol. 2021;doi: 10.1111/ced.15060.
Altemir, A., Iglesias-Sancho, M., Barrabés-Torrella, C., Sanchez-Regaña, M., & Salleras-Redonnet, M. (2021). Successful treatment of knee erythromelalgia with topical oxymetazoline. Clinical and experimental dermatology, . https://doi.org/10.1111/ced.15060
Altemir, Arcadi, et al. "Successful treatment of knee erythromelalgia with topical oxymetazoline." Clinical and experimental dermatology vol. (2021). doi: https://doi.org/10.1111/ced.15060
Altemir A, Iglesias-Sancho M, Barrabés-Torrella C, Sanchez-Regaña M, Salleras-Redonnet M. Successful treatment of knee erythromelalgia with topical oxymetazoline. Clin Exp Dermatol. 2021 Dec 14; doi: 10.1111/ced.15060. Epub 2021 Dec 14. PMID: 34905256.
Copy Download .nbib Format: NLM
Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials.

Clinical ophthalmology (Auckland, N.Z.)

Wirta DL, Korenfeld MS, Foster S, Smyth-Medina R, Bacharach J, Kannarr SR, Jaros MJ, Slonim CB.
PMID: 34675472
Clin Ophthalmol. 2021 Oct 08;15:4035-4048. doi: 10.2147/OPTH.S322326. eCollection 2021.

PURPOSE: An oxymetazoline 0.1% ophthalmic solution was recently approved for treatment of acquired blepharoptosis in adults. This study's objective was to evaluate the safety profile of oxymetazoline 0.1% when administered once daily for 14-84 days.PATIENTS AND METHODS: Pooled analysis...

Cite
Wirta DL, Korenfeld MS, Foster S, et al. Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials. Clin Ophthalmol. 2021;15:4035-4048doi: 10.2147/OPTH.S322326.
Wirta, D. L., Korenfeld, M. S., Foster, S., Smyth-Medina, R., Bacharach, J., Kannarr, S. R., Jaros, M. J., & Slonim, C. B. (2021). Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials. Clinical ophthalmology (Auckland, N.Z.), 154035-4048. https://doi.org/10.2147/OPTH.S322326
Wirta, David L, et al. "Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials." Clinical ophthalmology (Auckland, N.Z.) vol. 15 (2021): 4035-4048. doi: https://doi.org/10.2147/OPTH.S322326
Wirta DL, Korenfeld MS, Foster S, Smyth-Medina R, Bacharach J, Kannarr SR, Jaros MJ, Slonim CB. Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials. Clin Ophthalmol. 2021 Oct 08;15:4035-4048. doi: 10.2147/OPTH.S322326. eCollection 2021. PMID: 34675472; PMCID: PMC8517985.
Copy Download .nbib Format: NLM
Intranasal corticosteroid and oxymetazoline for chronic rhinitis: a systematic review.

The Journal of laryngology and otology

Neighbors CL, Salvador CF, Zhu B, Camacho M, Tsai P.
PMID: 34702392
J Laryngol Otol. 2021 Oct 27;1-9. doi: 10.1017/S0022215121003364. Epub 2021 Oct 27.

OBJECTIVE: This study aimed to summarise the evidence for efficacy of combination treatment of intranasal corticosteroid spray with oxymetazoline hydrochloride nasal spray for chronic rhinitis.METHOD: Nine databases were systematically searched from study inception in September 2016 to 1 June...

Cite
Neighbors CL, Salvador CF, Zhu B, et al. Intranasal corticosteroid and oxymetazoline for chronic rhinitis: a systematic review. J Laryngol Otol. 2021;1-9doi: 10.1017/S0022215121003364.
Neighbors, C. L., Salvador, C. F., Zhu, B., Camacho, M., & Tsai, P. (2021). Intranasal corticosteroid and oxymetazoline for chronic rhinitis: a systematic review. The Journal of laryngology and otology, 1-9. https://doi.org/10.1017/S0022215121003364
Neighbors, C L, et al. "Intranasal corticosteroid and oxymetazoline for chronic rhinitis: a systematic review." The Journal of laryngology and otology vol. (2021): 1-9. doi: https://doi.org/10.1017/S0022215121003364
Neighbors CL, Salvador CF, Zhu B, Camacho M, Tsai P. Intranasal corticosteroid and oxymetazoline for chronic rhinitis: a systematic review. J Laryngol Otol. 2021 Oct 27;1-9. doi: 10.1017/S0022215121003364. Epub 2021 Oct 27. PMID: 34702392.
Copy Download .nbib Format: NLM
Investigation of Repeatability of Peak Nasal Inspiratory Flow Rate Measurements Under Baseline Conditions and After Administration of 0.05% Oxymetazoline.

American journal of rhinology & allergy

Dor-Wojnarowska A, Radlińska A, Rabski M, Fal A, Liebhart J, Zaleska A, Babchyshyn M, Samoliński B.
PMID: 33957801
Am J Rhinol Allergy. 2022 Jan;36(1):41-46. doi: 10.1177/19458924211015584. Epub 2021 May 06.

OBJECTIVES: Peak nasal inspiratory flow (PNIF) measurement is an inexpensive and user-friendly method to assess nasal patency. However, the repeatability of PNIF measurements, as well as the threshold value of a change in PNIF, which can be considered significant...

Cite
Dor-Wojnarowska A, Radlińska A, Rabski M, et al. Investigation of Repeatability of Peak Nasal Inspiratory Flow Rate Measurements Under Baseline Conditions and After Administration of 0.05% Oxymetazoline. Am J Rhinol Allergy. 2021;36(1):41-46doi: 10.1177/19458924211015584.
Dor-Wojnarowska, A., Radlińska, A., Rabski, M., Fal, A., Liebhart, J., Zaleska, A., Babchyshyn, M., & Samoliński, B. (2022). Investigation of Repeatability of Peak Nasal Inspiratory Flow Rate Measurements Under Baseline Conditions and After Administration of 0.05% Oxymetazoline. American journal of rhinology & allergy, 36(1), 41-46. https://doi.org/10.1177/19458924211015584
Dor-Wojnarowska, Anna, et al. "Investigation of Repeatability of Peak Nasal Inspiratory Flow Rate Measurements Under Baseline Conditions and After Administration of 0.05% Oxymetazoline." American journal of rhinology & allergy vol. 36,1 (2022): 41-46. doi: https://doi.org/10.1177/19458924211015584
Dor-Wojnarowska A, Radlińska A, Rabski M, Fal A, Liebhart J, Zaleska A, Babchyshyn M, Samoliński B. Investigation of Repeatability of Peak Nasal Inspiratory Flow Rate Measurements Under Baseline Conditions and After Administration of 0.05% Oxymetazoline. Am J Rhinol Allergy. 2022 Jan;36(1):41-46. doi: 10.1177/19458924211015584. Epub 2021 May 06. PMID: 33957801.
Copy Download .nbib Format: NLM
alpha2-Adrenergic-receptor response in reversible increase in hemoglobin concentration in intermittent hypoxia.

Pathophysiology : the official journal of the International Society for Pathophysiology

Kuwahira I, Kamiya U, Iwamoto T, Ishii M, Moue Y, Ohta Y, Gonzalez NC.
PMID: 10996509
Pathophysiology. 2000 Sep;7(3):165-169. doi: 10.1016/s0928-4680(00)00047-x.

We have previously shown that intermittent hypoxia (IHx, 10% O(2), 60 min/day) leads to an increase in the splenic alpha2-adrenoceptor response and results in a splenic contraction-induced reversible increase in hemoglobin concentration ([Hb]). In the present study, we determined...

Cite
Kuwahira I, Kamiya U, Iwamoto T, et al. alpha2-Adrenergic-receptor response in reversible increase in hemoglobin concentration in intermittent hypoxia. Pathophysiology. 2000;7(3):165-169doi: 10.1016/s0928-4680(00)00047-x.
Kuwahira, I., Kamiya, U., Iwamoto, T., Ishii, M., Moue, Y., Ohta, Y., & Gonzalez, N. C. (2000). alpha2-Adrenergic-receptor response in reversible increase in hemoglobin concentration in intermittent hypoxia. Pathophysiology : the official journal of the International Society for Pathophysiology, 7(3), 165-169. https://doi.org/10.1016/s0928-4680(00)00047-x
Kuwahira, et al. "alpha2-Adrenergic-receptor response in reversible increase in hemoglobin concentration in intermittent hypoxia." Pathophysiology : the official journal of the International Society for Pathophysiology vol. 7,3 (2000): 165-169. doi: https://doi.org/10.1016/s0928-4680(00)00047-x
Kuwahira I, Kamiya U, Iwamoto T, Ishii M, Moue Y, Ohta Y, Gonzalez NC. alpha2-Adrenergic-receptor response in reversible increase in hemoglobin concentration in intermittent hypoxia. Pathophysiology. 2000 Sep;7(3):165-169. doi: 10.1016/s0928-4680(00)00047-x. PMID: 10996509.
Copy Download .nbib Format: NLM
Phase 1 pharmacokinetics and phase 3 efficacy of testosterone nasal gel in subjects with seasonal allergies.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada

Rogol AD, Tkachenko N, Badorrek P, Hohlfeld JM, Bryson N.
PMID: 29603916
Can Urol Assoc J. 2018 Jul;12(7):E349-E356. doi: 10.5489/cuaj.4898. Epub 2018 Mar 19.

INTRODUCTION: NATESTOMETHODS: The 24-hour pharmacokinetics (PK) and relative bioavailability of serum total testosterone (sTT) from TNG (11 mg tid ) were determined using a phase 1 Latin-square design with 18 eugonadal AR subjects crossed over between asymptomatic, symptomatic-untreated, and...

Cite
Rogol AD, Tkachenko N, Badorrek P, et al. Phase 1 pharmacokinetics and phase 3 efficacy of testosterone nasal gel in subjects with seasonal allergies. Can Urol Assoc J. 2018;12(7):E349-E356doi: 10.5489/cuaj.4898.
Rogol, A. D., Tkachenko, N., Badorrek, P., Hohlfeld, J. M., & Bryson, N. (2018). Phase 1 pharmacokinetics and phase 3 efficacy of testosterone nasal gel in subjects with seasonal allergies. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 12(7), E349-E356. https://doi.org/10.5489/cuaj.4898
Rogol, Alan D, et al. "Phase 1 pharmacokinetics and phase 3 efficacy of testosterone nasal gel in subjects with seasonal allergies." Canadian Urological Association journal = Journal de l'Association des urologues du Canada vol. 12,7 (2018): E349-E356. doi: https://doi.org/10.5489/cuaj.4898
Rogol AD, Tkachenko N, Badorrek P, Hohlfeld JM, Bryson N. Phase 1 pharmacokinetics and phase 3 efficacy of testosterone nasal gel in subjects with seasonal allergies. Can Urol Assoc J. 2018 Jul;12(7):E349-E356. doi: 10.5489/cuaj.4898. Epub 2018 Mar 19. PMID: 29603916; PMCID: PMC6118055.
Copy Download .nbib Format: NLM
Intranasal tetracaine and oxymetazoline: a newly approved drug formulation that provides maxillary dental anesthesia without needles.

Current medical research and opinion

Hersh EV, Saraghi M, Moore PA.
PMID: 27646144
Curr Med Res Opin. 2016 Nov;32(11):1919-1925. doi: 10.1080/03007995.2016.1238352. Epub 2016 Oct 03.

BACKGROUND: An intranasal formulation of 3% tetracaine and 0.05% oxymetazoline (Kovanaze) received FDA approval on 29 June 2016. This formulation appears to provide sufficient local anesthesia to perform routine dental restorative (filling) procedures in maxillary teeth from second premolar...

Cite
Hersh EV, Saraghi M, Moore PA. Intranasal tetracaine and oxymetazoline: a newly approved drug formulation that provides maxillary dental anesthesia without needles. Curr Med Res Opin. 2016;32(11):1919-1925doi: 10.1080/03007995.2016.1238352.
Hersh, E. V., Saraghi, M., & Moore, P. A. (2016). Intranasal tetracaine and oxymetazoline: a newly approved drug formulation that provides maxillary dental anesthesia without needles. Current medical research and opinion, 32(11), 1919-1925. https://doi.org/10.1080/03007995.2016.1238352
Hersh, Elliot V, et al. "Intranasal tetracaine and oxymetazoline: a newly approved drug formulation that provides maxillary dental anesthesia without needles." Current medical research and opinion vol. 32,11 (2016): 1919-1925. doi: https://doi.org/10.1080/03007995.2016.1238352
Hersh EV, Saraghi M, Moore PA. Intranasal tetracaine and oxymetazoline: a newly approved drug formulation that provides maxillary dental anesthesia without needles. Curr Med Res Opin. 2016 Nov;32(11):1919-1925. doi: 10.1080/03007995.2016.1238352. Epub 2016 Oct 03. PMID: 27646144.
Copy Download .nbib Format: NLM
Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology

Tomillero A, Moral MA.
PMID: 20664824
Methods Find Exp Clin Pharmacol. 2010 Jun;32(5):331-88. doi: 10.1358/mf.2010.32.5.1520420.

[¹¹C]RAC; (18)F-Fluoromisonidazole; 89-12; 9-[¹⁸F]Fluoropropyl-(+)-dihydrotetrabenazine; Adalimumab, Adecatumumab, ADMVA, ADXS-11-001, Aflibercept, Agatolimod sodium, AGS-004, Alglucosidase alfa, Aliskiren fumarate, Alvocidib hydrochloride, AMG-108, AMG-853, Apixaban, Aripiprazole, Armodafinil, Atazanavir sulfate, Atomoxetine hydrochloride; Bevacizumab, BioMatrix Flex drug eluting stent, Biphasic insulin aspart, Bortezomib, Bosentan; Caspofungin...

Cite
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010;32(5):331-88doi: 10.1358/mf.2010.32.5.1520420.
Tomillero, A., & Moral, M. A. (2010). Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology, 32(5), 331-88. https://doi.org/10.1358/mf.2010.32.5.1520420
Tomillero, A, and Moral, M A. "Gateways to clinical trials." Methods and findings in experimental and clinical pharmacology vol. 32,5 (2010): 331-88. doi: https://doi.org/10.1358/mf.2010.32.5.1520420
Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jun;32(5):331-88. doi: 10.1358/mf.2010.32.5.1520420. PMID: 20664824.
Copy Download .nbib Format: NLM
Oxymetazoline plus dexpanthenol in nasal congestion.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India

Jagade MV, Langade DG, Pophale RR, Prabhu A.
PMID: 23120592
Indian J Otolaryngol Head Neck Surg. 2008 Dec;60(4):393-7. doi: 10.1007/s12070-008-0125-7. Epub 2009 Jan 28.

AIMS: To compare the efficacy and tolerability of Oxymetazoline 0.05 % plus Dexpanthanol 5% versus Xylometazoline 0.1 % nasal drops in patients with nasal congestion due to allergic rhinitis and following nasal surgery.METHODS: An investigator-blind, randomized, controlled, phase IV...

Cite
Jagade MV, Langade DG, Pophale RR, et al. Oxymetazoline plus dexpanthenol in nasal congestion. Indian J Otolaryngol Head Neck Surg. 2009;60(4):393-7doi: 10.1007/s12070-008-0125-7.
Jagade, M. V., Langade, D. G., Pophale, R. R., & Prabhu, A. (2008). Oxymetazoline plus dexpanthenol in nasal congestion. Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India, 60(4), 393-7. https://doi.org/10.1007/s12070-008-0125-7
Jagade, Mohan V, et al. "Oxymetazoline plus dexpanthenol in nasal congestion." Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India vol. 60,4 (2008): 393-7. doi: https://doi.org/10.1007/s12070-008-0125-7
Jagade MV, Langade DG, Pophale RR, Prabhu A. Oxymetazoline plus dexpanthenol in nasal congestion. Indian J Otolaryngol Head Neck Surg. 2008 Dec;60(4):393-7. doi: 10.1007/s12070-008-0125-7. Epub 2009 Jan 28. PMID: 23120592; PMCID: PMC3476802.
Copy Download .nbib Format: NLM
The thermodynamic dissociation constants of ambroxol, antazoline, naphazoline, oxymetazoline and ranitidine by the regression analysis of spectrophotometric data.

Talanta

Meloun M, Syrový T, Vrána A.
PMID: 18969326
Talanta. 2004 Feb 27;62(3):511-22. doi: 10.1016/j.talanta.2003.08.027.

The mixed dissociation constants of five drug acids-ambroxol, antazoline, naphazoline, oxymetazoline and ranitidine-at various ionic strengths I of range 0.01 and 1.0 and at temperatures of 25 and 37 degrees C were determined using SQUAD(84) regression analysis of the...

Cite
Meloun M, Syrový T, Vrána A. The thermodynamic dissociation constants of ambroxol, antazoline, naphazoline, oxymetazoline and ranitidine by the regression analysis of spectrophotometric data. Talanta. 2004;62(3):511-22doi: 10.1016/j.talanta.2003.08.027.
Meloun, M., Syrový, T., & Vrána, A. (2004). The thermodynamic dissociation constants of ambroxol, antazoline, naphazoline, oxymetazoline and ranitidine by the regression analysis of spectrophotometric data. Talanta, 62(3), 511-22. https://doi.org/10.1016/j.talanta.2003.08.027
Meloun, Milan, et al. "The thermodynamic dissociation constants of ambroxol, antazoline, naphazoline, oxymetazoline and ranitidine by the regression analysis of spectrophotometric data." Talanta vol. 62,3 (2004): 511-22. doi: https://doi.org/10.1016/j.talanta.2003.08.027
Meloun M, Syrový T, Vrána A. The thermodynamic dissociation constants of ambroxol, antazoline, naphazoline, oxymetazoline and ranitidine by the regression analysis of spectrophotometric data. Talanta. 2004 Feb 27;62(3):511-22. doi: 10.1016/j.talanta.2003.08.027. PMID: 18969326.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 52 entries